Inflammation and cancer: Causes and consequences

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 504-508

  Moore, M M ^a,b   Chua, W ^a,b   Charles, K A ^b   Clarke, S J ^a,b  

^a Department of Geriatric Medicine   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASBESTOS; C REACTIVE PROTEIN; CYTOCHROME P450 3A; CYTOKINE; DEXAMETHASONE; DOCETAXEL; ERYTHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OROSOMUCOID; PREALBUMIN; PROTEIN RET; SILICON DIOXIDE; TUMOR MARKER;

ALBUMIN BLOOD LEVEL; ANUS CANCER; BARRETT ESOPHAGUS; BLADDER CANCER; BURKITT LYMPHOMA; CANCER THERAPY; CHRONIC INFLAMMATION; CHRONIC PANCREATITIS; COLORECTAL CANCER; CYSTITIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG METABOLISM; ENTERITIS; EPSTEIN BARR VIRUS; ESOPHAGUS CANCER; GENE EXPRESSION REGULATION; GLASGOW PROGNOSTIC SCORE; HELICOBACTER INFECTION; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN HERPESVIRUS 8; INJURY SCALE; KAPOSI SARCOMA; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOCYTE COUNT; MESOTHELIOMA; METASTASIS; MOLECULAR MECHANICS; NASOPHARYNX CARCINOMA; NEOPLASM; NEUTROPHIL COUNT; OVARY CANCER; PANCREAS CANCER; PAPILLOMA VIRUS; PATHOPHYSIOLOGY; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHISTOSOMIASIS; SMOKING; STOMACH CANCER; THROMBOCYTE COUNT; TISSUE INJURY; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; NEOPLASMS; RISK FACTORS;

EID: 77949875770     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.254     Document Type: Review

References (33)

1. Balkwill F. & Mantovani a. Infammation and cancer: back to Virchow? [see comment]. Lancet 357, 539-545 (2001).
2. Munkholm, P. Review article: the incidence and prevalence of colorectal cancer in infammatory bowel disease. Aliment. Pharmacol. Ther. 18 (suppl. 2), 1-5 (2003).
3. Hussain, S.P. & Harris, C.C. Infammation and cancer: an ancient link with novel potentials. Int. J. Cancer 121, 2373-2380 (2007).
4. Valinluck, V. & Sowers, L.C. Infammation-mediated cytosine damage: a mechanistic link between infammation and the epigenetic alterations in human cancers. Cancer Res. 67, 5583-5586 (2007).
5. Borrello, M.G. et al. Induction of a proinfammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. U.S.A. 102, 14825-14830 (2005).
6. Mantovani, a., allavena, P., Sica, a. & Balkwill, F. Cancer-related infammation. Nature 454, 436-444 (2008).
7. Dalal, S. & Zhukovsky, D.S. Pathophysiology and management of fever. J. Support. Oncol. 4, 9-16 (2006).
8. Lister, T.a. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting [erratum appears in. J. Clin. Oncol. 8, 1602 (1990)]. J Clin Oncol. 7, 1630-1636 (1989).
9. Ebrahimi, B., Tucker, S.L., Li, D., abbruzzese, J.L. & Kurzrock, R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101, 2727-2736 (2004).
10. Pftzenmaier, J., Vessella, R., Higano, C.S., Noteboom, J.L., Wallace, D. Jr & Corey, E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97, 1211-1216 (2003).
11. Rivory, L.P., Slaviero, K.a. & Clarke, S.J. Hepatic cytochrome P450 3a drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer 87, 277-280 (2002).
12. Charles, K.a. et al. Predicting the toxicity of weekly docetaxel in advanced cancer. Clin. Pharmacokinet. 45, 611-622 (2006).
13. Alexandre, J. et al. Evaluation of the nutritional and infammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann. Oncol. 14, 36-41 (2003).
14. Sharma, R., Cunningham, D., Smith, P., Robertson, G., Dent, O. & Clarke, S.J. Infammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients\analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer 9, 153 (2009).
15. Leggas, M. et al. Intensive anti-infammatory therapy with dexamethasone in patients with non-small cell lung cancer: efect on chemotherapy toxicity and efcacy. Cancer Chemother. Pharmacol. 63, 731-743 (2009).
16. Wang, H., Li, M., Rinehart, J.J. & Zhang, R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin. Cancer Res. 10, 1633-1644 (2004).
17. Trikha, M., Corringham, R., Klein, B. & Rossi, J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9, 4653-4665 (2003).
18. Chung, Y.C. & Chang, Y.F. Serum interleukin-6 levels refect the disease status of colorectal cancer. J. Surg. Oncol. 83, 222-226 (2003).
19. De Vita, F. et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J. Interferon Cytokine Res. 21, 45-52 (2001).
20. Shariat, S.F. et al. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J. Clin. Oncol. 26, 1526-1531 (2008)
21. Ledur, a., Fitting, C., David, B., Hamberger, C. & Cavaillon, J.M. Variable estimates of cytokine levels produced by commercial ELISa kits: results using international cytokine standards. J. Immunol. Methods 186, 171-179 (1995).
22. Heikkilä, K., Ebrahim, S. & Lawlor, D.a. a systematic review of the association between circulating concentrations of C reactive protein and cancer. J. Epidemiol. Community Health 61, 824-833 (2007).
23. Tsilidis, K.K., Branchini, C., Guallar, E., Helzlsouer, K.J., Erlinger, T.P. & Platz, E.a. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int. J. Cancer 123, 1133-1140 (2008).
24. Hilmy, M., Bartlett, J.M., Underwood, M.a. & McMillan, D.C. The relationship between the systemic infammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br. J. Cancer 92, 625-627 (2005).
25. Crumley, a.B., McMillan, D.C., McKernan, M., Going, J.J., Shearer, C.J. & Stuart, R.C. an elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specifc survival in patients undergoing resection for gastro-oesophageal cancer. Br. J. Cancer 94, 1568-1571 (2006).
26. Karakiewicz, P.I. et al. C-reactive protein is an informative predictor of renal cell carcinoma-specifc mortality. Cancer 110, 1241-1247 (2007).
27. Scott, H.R., McMillan, D.C., Forrest, L.M., Brown, D.J., Mcardle, C.S. & Milroy, R. The systemic infammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br. J. Cancer 87, 264-267 (2002).
28. Beer, T.M. et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer. Cancer 112, 2377-2383 (2008).
29. Forrest, L.M., McMillan, D.C., Mcardle, C.S., angerson, W.J. & Dunlop, D.J. Evaluation of cumulative prognostic scores based on the systemic infammatory response in patients with inoperable non-small-cell lung cancer. Br. J. Cancer 89, 1028-1030 (2003).
30. McMillan, D.C. Systemic infammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 12, 223-226 (2009).
31. Walsh, S.R., Cook, E.J., Goulder, F., Justin, T.a. & Keeling, N.J. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol. 91, 181-184 (2005).
32. Yamanaka, T., Matsumoto, S., Teramukai, S., Ishiwata, R., Nagai, Y. & Fukushima, M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 73, 215-220 (2007).
33. Smith, R.a. et al. Preoperative platelet-lymphocyte ratio is an independent signifcant prognostic marker in resected pancreatic ductal adenocarcinoma. Am. J. Surg. 197, 466-472 (2009).